Table 1. Demographic and Clinical Characteristics of Patients at Baseline.
| Characteristic | No. (%) | ||
|---|---|---|---|
| All (n = 126) | Tocilizumab (n = 60) | Standard care (n = 66) | |
| Age, median (IQR), y | 60.0 (53.0-72.0) | 61.5 (51.5-73.5) | 60.0 (54.0-69.0) |
| Sex | |||
| Male | 77 (61.1) | 40 (66.7) | 37 (56.1) |
| Female | 49 (38.9) | 20 (33.3) | 29 (43.9) |
| Days from symptom onset to randomization, median (IQR) | 8.0 (6.0-11.0) | 7.0 (4.0-11.0) | 8.0 (6.0-11.0) |
| Days from hospital admission to randomization, median (IQR) | 2 (1-3.2) | 2 (1-3) | 2 (1-4.2) |
| Coexisting conditions | |||
| Diabetes mellitus | 19 (15.1) | 10 (16.7) | 9 (13.6) |
| Obesity (BMI ≥ 30)a | 38 (32.2) | 16 (28.1) | 22 (36.1) |
| Hypertension | 56 (44.4) | 27 (45.0) | 29 (43.9) |
| COPD | 4 (3.2) | 2 (3.3) | 2 (3.0) |
| Body temperature, median (IQR), °C | 38.0 (36.9-38.5) | 38.0 (37.0-38.4) | 38.0 (36.8-38.5) |
| Respiratory rate, median (IQR), breaths/min | 20.0 (18.0-24.0) | 20.0 (18.0-24.0) | 20.0 (18.0-24.0) |
| Unknown | 13 (10.3) | 7 (11.7) | 6 (9.1) |
| C-Reactive protein, median (IQR), mg/dL | 8.2 (3.7-13.5) | 10.5 (5.0-14.6) | 6.5 (3.2-11.8) |
| White blood cell count, median (IQR), /μL | 5700 (4600-7500) | 5800 (4400-7600) | 5600 (4700-7200) |
| Unknown | 2 (1.6) | 1 (1.7) | 1 (1.5) |
| Lymphocyte count, median (IQR), /μL | 900 (700-1300) | 1000 (800-1300) | 900 (700-1200) |
| Unknown | 13 (10.3) | 8 (13.3) | 5 (7.6) |
| Platelet count, median (IQR), ×103/μL | 200.5 (158.0-253.5) | 213.0 (165.0-268.0) | 188.0 (152.0-246.0) |
| Unknown | 2 (1.6) | 1 (1.7) | 1 (1.5) |
| Pao2/Fio2 median (IQR), mm Hg | 264.5 (243.0-290.0) | 262.5 (241.0-286.5) | 268.2 (244.0-290.0) |
| Ferritin, median (IQR), ng/mL | 569.0 (317.0-1156.0) | 646.0 (289.2-1107.5) | 533.5 (351.0-1184.0) |
| Unknown | 17 (13.5) | 9 (15.0) | 8 (12.1) |
| D-Dimer, median (IQR), μg/mL | 0.566 (0.367-0.956) | 0.756 (0.480-1.070) | 0.455 (0.326-0.810) |
| Unknown | 11 (8.7) | 6 (10.0) | 5 (7.6) |
| IL-6, median (IQR), pg/mL | 42.1 (20.6-74.9) | 50.4 (28.3-93.2) | 34.3 (19.0-59.3) |
| Unknown | 20 (15.9) | 9 (15.0) | 11 (16.7) |
| Hydroxychloroquine | 115 (91.3) | 53 (88.3) | 62 (93.9) |
| Heparin and LMWH | 81 (64.3) | 41 (68.3) | 40 (60.6) |
| Antiretroviralsb | 52 (41.3) | 21 (35.0) | 31 (47.0) |
| Azithromycin | 26 (20.6) | 10 (16.7) | 16 (24.2) |
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; IL-6, interleukin-6; IQR, interquartile range; LMWH, low-molecular-weight heparin; Pao2/Fio2, partial pressure of arterial oxygen/fraction of inspired oxygen.
a
Calculated as weight in kilograms divided by height in meters squared.
b
Antiretrovirals included darunavir/cobicistat, darunavir/ritonavir, or lopinavir/ritonavir. No remdesivir was administered.
SI conversion factors: To convert C-reactive protein to mg/L, multiply by 10; D-dimer to nmol/L, multiply by 5.476; ferritin to μg/L, multiply by 1.0; lymphocyte count to ×109/L, multiply by 0.001; platelet count to ×109/L, multiply by 1.0; white blood cell count to ×109/L, multiply by 0.001.